Skip to content
Clinical Trials – home
HungaryBack to Hungary

Clinical trials in Salgotarjan

270 clinical trials in Salgotarjan, Hungary. Every trial is listed in the EU Clinical Trials Register and updated daily.

Salgotarjan at a glance
270
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

270 trials in Salgotarjan

Open in trial search

Bronchiectasis

Recruiting

Study of BI 1291583 tablets taken once daily for 76 weeks in adults with bronchiectasis

Investigational
Countries:HungaryHungary
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:BI 1291583
  • Sponsor:Boehringer Ingelheim Espana S.A.

Cardiac failure

Recruiting

Study of maridebart cafraglutide for patients with heart failure with preserved or mildly reduced ejection fraction and obesity

Investigational
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Maridebart Cafraglutide
  • Sponsor:Amgen Inc.

Effect of lenbelintide (AZD6234) on body weight in adults with type 2 diabetes and obesity or overweight

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:AZD6234
  • Sponsor:Astrazeneca AB

A study to assess the effect of elecoglipron alone and in combination with dapagliflozin on blood sugar control in adults with Type 2 diabetes

Registered drug
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:AZD5004
  • Sponsor:Astrazeneca AB

A Phase III Study of Elecoglipron Compared with Semaglutide for Adults with Type 2 Diabetes Mellitus

Registered drugNo placebo
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:AZD5004
  • Sponsor:Astrazeneca AB

Study of LY4268989 adipic acid in adults with moderately to severely active ulcerative colitis

Investigational
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:LY4268989 adipic acid
  • Sponsor:Eli Lilly & Co.

A Phase 3 Randomized Study of mRNA‑4157 plus Pembrolizumab as Adjuvant Therapy in Patients with Completely Resected Stage I Non‑Small Cell Lung Cancer

Investigational
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:MRNA-4157
  • Sponsor:Merck Sharp & Dohme LLC

Crohn's disease

Recruiting

A study to evaluate the effectiveness and safety of duvakitug in patients with moderate to severe Crohn's disease

Investigational
Countries:HungaryHungary
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Duvakitug
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Crohn's disease

Recruiting

A study to evaluate the efficacy and safety of duvakitug in patients with moderate to severe Crohn's disease

Investigational
Countries:HungaryHungary
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Duvakitug
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Phase III Randomized Study of Rilvegostomig vs. Pembrolizumab with Platinum-based Chemotherapy in PD-L1 Expressing Metastatic Squamous NSCLC

Registered drugNo placebo
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Astrazeneca AB

A study of duvakitug for patients with moderately to severely active ulcerative colitis to see if it works and is safe as maintenance therapy

Investigational
Countries:HungaryHungary
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Duvakitug
  • Sponsor:Sanofi-Aventis Recherche & Developpement

A study testing duvakitug for patients with moderately to severely active ulcerative colitis

Investigational
Countries:HungaryHungary
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Duvakitug
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Other cities in Hungary

The busiest research cities in the country

All 73 cities in Hungary

Clinical research in Salgotarjan

What the registry says about research in the country

01 Breast Cancer Research

Innovative clinical trials focusing on hormone receptor-positive and HER2-negative breast cancer treatments, including studies of novel therapeutic combinations and targeted therapies.

  • Advanced metastatic breast cancer treatments
  • Triple-negative breast cancer therapies
  • Hormone therapy resistance studies

Research includes evaluation of new drug combinations and sequential therapy approaches for improved patient outcomes.

02 Lung Cancer Studies

Groundbreaking research on non-small cell lung cancer treatments, particularly focusing on advanced and metastatic cases with specific biomarker profiles.

  • PD-L1 positive NSCLC treatments
  • Combination immunotherapy approaches
  • Stage III unresectable cancer therapies

Studies emphasize personalized treatment approaches based on molecular markers.

03 Head and Neck Cancer

Clinical trials investigating new treatments for head and neck squamous cell carcinoma, including both HPV-negative and recurrent/metastatic cases.

  • Novel combination therapies
  • Immunotherapy applications
  • Treatment for recurrent disease

Research focuses on improving survival rates through innovative therapeutic combinations.

04 Prostate Cancer Innovations

Studies addressing metastatic castration-resistant prostate cancer, evaluating new treatment options and therapeutic combinations.

  • Novel hormonal therapies
  • Treatment-resistant cases
  • Combination therapy approaches

Trials aim to improve outcomes for patients with advanced disease stages.

05 Cardiovascular Research

Studies examining treatments for cardiovascular diseases and related conditions, including stroke prevention and obesity management.

  • Acute ischemic stroke treatments
  • Obesity management in CVD patients
  • Prevention strategies

Research focuses on both therapeutic interventions and preventive approaches.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.